178 related articles for article (PubMed ID: 31704613)
1. APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
Siraj AK; Kumar Parvathareddy S; Pratheeshkumar P; Padmaja Divya S; Ahmed SO; Melosantos R; Begum R; Concepcion RMJA; Al-Sanea N; Ashari LH; Abduljabbar A; Al-Dayel F; Al-Kuraya KS
Biomed Pharmacother; 2020 Jan; 121():109572. PubMed ID: 31704613
[TBL] [Abstract][Full Text] [Related]
2.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
3. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
4. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy.
Martino-Echarri E; Henderson BR; Brocardo MG
Oncotarget; 2014 Oct; 5(20):9889-900. PubMed ID: 25301724
[TBL] [Abstract][Full Text] [Related]
5. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H
Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472
[TBL] [Abstract][Full Text] [Related]
6. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H
Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
8. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
[TBL] [Abstract][Full Text] [Related]
9. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS
Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer.
Zhang Y; Guo L; Li Y; Feng GH; Teng F; Li W; Zhou Q
Mol Cancer; 2018 Jan; 17(1):1. PubMed ID: 29304823
[TBL] [Abstract][Full Text] [Related]
11. Survival of APC-mutant colorectal cancer cells requires interaction between tankyrase and a thiol peroxidase, peroxiredoxin II.
Kang DH; Lee JHS; Kang SW
BMB Rep; 2017 Aug; 50(8):391-392. PubMed ID: 28683851
[TBL] [Abstract][Full Text] [Related]
12. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.
Schell MJ; Yang M; Teer JK; Lo FY; Madan A; Coppola D; Monteiro AN; Nebozhyn MV; Yue B; Loboda A; Bien-Willner GA; Greenawalt DM; Yeatman TJ
Nat Commun; 2016 Jun; 7():11743. PubMed ID: 27302369
[TBL] [Abstract][Full Text] [Related]
13. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
[TBL] [Abstract][Full Text] [Related]
14. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.
Christie M; Jorissen RN; Mouradov D; Sakthianandeswaren A; Li S; Day F; Tsui C; Lipton L; Desai J; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Simpson AJ; Tomlinson IP; Gibbs P; Sieber OM
Oncogene; 2013 Sep; 32(39):4675-82. PubMed ID: 23085758
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway.
Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Tamir T; Jain V; Bharatam PV; Wyatt MD; Kundu CN
DNA Repair (Amst); 2014 Dec; 24():15-25. PubMed ID: 25460919
[TBL] [Abstract][Full Text] [Related]
16. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
17. Targeted deep sequencing reveals
Chen X; Hu M; Chen Y; Li A; Hua Y; Jiang H; Li H; Lin M
Scand J Gastroenterol; 2022 Apr; 57(4):465-472. PubMed ID: 34978498
[No Abstract] [Full Text] [Related]
18. Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells.
Kang DH; Lee DJ; Lee S; Lee SY; Jun Y; Kim Y; Kim Y; Lee JS; Lee DK; Lee S; Jho EH; Yu DY; Kang SW
Nat Commun; 2017 Jun; 8(1):40. PubMed ID: 28659575
[TBL] [Abstract][Full Text] [Related]
19. Origin of Somatic Mutations in β-Catenin versus Adenomatous Polyposis Coli in Colon Cancer: Random Mutagenesis in Animal Models versus Nonrandom Mutagenesis in Humans.
Yang D; Zhang M; Gold B
Chem Res Toxicol; 2017 Jul; 30(7):1369-1375. PubMed ID: 28578586
[TBL] [Abstract][Full Text] [Related]
20. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
